The genetic test after resistance to dacomitinib was negative. What other targeted drugs are available in the future?

When lung cancer patients develop drug resistance after using dacomitinib (Dacomitinib) to treat EGFR mutated non-small cell lung cancer (NSCLC), and the genetic test results show "negative", that is, no clear resistance mechanism has been found, patients and doctors often find themselves in a dilemma. In fact, negative genetic testing does not mean that there is no resistance mechanism, but that the real molecular changes may not be captured due to insufficient sampling locations, low mutation abundance, and limitations of detection technology. At this time, there are still a variety of clinical strategies to choose from. The following are currently more common follow-up targeted treatment directions:

1. Consider using third-generation EGFR-TKI, such as Osimertinib

Even ifdrug resistance mutations such as T790M are not detected, some patients may still benefit from osimertinib after becoming dacomitinib resistant. Multiple overseas real-world data show that some patients who are resistant to dacomitinib but have no detectable T790M mutation can still observe disease control after using osimertinib. This may be related to the stronger EGFR inhibition breadth and better central nervous system penetration of osimertinib, so osimertinib may still be used as an empiric treatment option in the case of negative genetic testing.

2. Combination treatment strategies are worth exploring

When the effect of a single targeted therapy weakens, the combination of other pathway inhibitors may lead to breakthroughs. For exampleEGFR-TKI combined with anti-angiogenic drugs such as bevacizumab, or trying the combination of EGFR-TKI with MEK inhibitors and MET inhibitors. In some overseas studies, for patients with negative genetic testing but imaging evidence of progression, the combination regimen can help delay the evolution of drug resistance mechanisms, and is especially suitable for patients with low progression in the lungs or insensitive lesions in specific areas.

3. More advanced molecular detection technology should be paid attention to

Currently used liquid biopsies or tissue tests still have limitations. It is recommended that patients undergo a more sensitive testing platform when conditions permit, such as a comprehensive gene panel based on high-throughput sequencing (NGS). This technology can cover a wider range of mutation, fusion and amplification information, and sometimes can discover new clues that were not exposed in the initial test, such as HER2, BRAF or PIK3CA mutations, etc., providing a basis for further targeted treatment.

4. Consider MET amplification or EGFR bypass activation

Although the genetic test was negative,Bypass activation mechanisms such as MET amplification, HER3 upregulation, and enhanced AXL activity may still exist. These changes are sometimes difficult to capture with routine testing but may be the real drivers of clinical resistance. If the involvement of the accessory pathway mechanism is highly suspected, the introduction of MET inhibitors (such as capmatinib, crizotinib) or other inhibitors of the HER family can be considered for trial treatment.

5. Possibility of switching to chemotherapy or immunotherapy

When targeted therapy channels are blocked, traditional chemotherapy such as pemetrexed combined with platinum-based regimens is still one of the main treatments for dacomitinib resistance. In some patients, the immune microenvironment changes after resistance to targeted therapy. Immunotherapy (such asPD-1/PD-L1 inhibitors) may bring certain benefits, especially in patients with TP53 mutations or elevated PD-L1 expression.

6. Clinical trials are an important way to overcome difficulties

Clinical research on EGFR-TKI resistance continues to be carried out globally, especially in the fields of multi-target inhibitors and new antibody drug conjugates (ADCs), providing new treatment directions for patients. For patients whose resistance mechanisms cannot be clarified, participating in cutting-edge clinical trials can not only receive the most advanced treatments, but may also buy time for disease control.

To sum up, a negative gene test after dacomitinib resistance does not mean that there is no drug available, but it suggests that a more flexible and personalized treatment strategy should be adopted, including switching to other generationTKI drugs, considering combination therapy, upgrading molecular testing, or switching to chemotherapy and clinical research channels. Patients should not lose confidence because of a "negative" test result, but should work with an experienced oncologist to evaluate and develop a scientific and reasonable follow-up treatment path.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro